206 related articles for article (PubMed ID: 32051554)
1. Genetic basis for iMCD-TAFRO.
Yoshimi A; Trippett TM; Zhang N; Chen X; Penson AV; Arcila ME; Pichardo J; Baik J; Sigler A; Harada H; Fajgenbaum DC; Dogan A; Abdel-Wahab O; Xiao W
Oncogene; 2020 Apr; 39(15):3218-3225. PubMed ID: 32051554
[TBL] [Abstract][Full Text] [Related]
2. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Campylobacter jejuni infection in patients with Castleman-Kojima disease (idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO) syndrome).
Kageyama C; Igawa T; Gion Y; Iwaki N; Tabata T; Tanaka T; Kondo E; Sakai H; Tsuneyama K; Nomoto K; Noguchi H; Yoshino T; Yokota K; Sato Y
Pathol Int; 2019 Oct; 69(10):572-579. PubMed ID: 31631463
[TBL] [Abstract][Full Text] [Related]
4. International definition of iMCD-TAFRO: future perspectives.
Nishimura Y; Nishimura MF; Sato Y
J Clin Exp Hematop; 2022 Jun; 62(2):73-78. PubMed ID: 35474036
[TBL] [Abstract][Full Text] [Related]
5. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S
Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500
[TBL] [Abstract][Full Text] [Related]
6. TAFRO Syndrome: A Disease Requiring Immediate Medical Attention.
Masaki Y; Ueda Y; Yanagisawa H; Arita K; Sakai T; Yamada K; Mizuta S; Fukushima T; Takai K; Aoki S; Kawabata H
Intern Med; 2023 Jan; 62(1):27-32. PubMed ID: 35598998
[TBL] [Abstract][Full Text] [Related]
7. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
[TBL] [Abstract][Full Text] [Related]
8. Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
Phillips AD; Kakkis JJ; Tsao PY; Pierson SK; Fajgenbaum DC
J Cell Mol Med; 2022 Jun; 26(11):3147-3152. PubMed ID: 35488725
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly syndrome: a retrospective study from a large Western cohort.
Maisonobe L; Bertinchamp R; Damian L; Gérard L; Berisha M; Guillet S; Fieschi C; Malphettes M; Fadlallah J; Hié M; Dunogué B; De Wilde V; Vandergheynst F; Zafrani L; Grall M; Saada N; Garzaro M; Oksenhendler E; Galicier L; Boutboul D
Br J Haematol; 2022 Feb; 196(3):599-605. PubMed ID: 34585382
[TBL] [Abstract][Full Text] [Related]
10. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease?
Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y
Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.
Iwaki N; Gion Y; Kondo E; Kawano M; Masunari T; Moro H; Nikkuni K; Takai K; Hagihara M; Hashimoto Y; Yokota K; Okamoto M; Nakao S; Yoshino T; Sato Y
Sci Rep; 2017 Feb; 7():42316. PubMed ID: 28205564
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Belyaeva E; Rubenstein A; Pierson SK; Dalldorf D; Frank D; Lim MS; Fajgenbaum DC
Hematol Oncol; 2022 Apr; 40(2):191-201. PubMed ID: 35104370
[TBL] [Abstract][Full Text] [Related]
13. TAFRO Syndrome.
Igawa T; Sato Y
Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
[TBL] [Abstract][Full Text] [Related]
14. Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
Pai RL; Japp AS; Gonzalez M; Rasheed RF; Okumura M; Arenas D; Pierson SK; Powers V; Layman AAK; Kao C; Hakonarson H; van Rhee F; Betts MR; Kambayashi T; Fajgenbaum DC
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376796
[TBL] [Abstract][Full Text] [Related]
15. TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?
Takai K
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540266
[TBL] [Abstract][Full Text] [Related]
16. The potential role of follicular helper T cells in idiopathic multicentric Castleman disease with and without TAFRO syndrome.
Kurose N; Guo X; Shioya A; Mizutani KI; Kumagai M; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Nakamura S; Yamada S
Pathol Res Pract; 2019 Oct; 215(10):152563. PubMed ID: 31358479
[TBL] [Abstract][Full Text] [Related]
17. Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types: Implications for the mTOR signaling pathway.
Sumiyoshi R; Koga T; Fukui S; Furukawa K; Momoki M; Ichinose K; Yano S; Kawakami A
Clin Immunol; 2023 Nov; 256():109798. PubMed ID: 37778714
[TBL] [Abstract][Full Text] [Related]
18. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
19. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
20. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
